Antares Pharma Stock Forecast, Price & News

-0.06 (-1.43 %)
(As of 06/18/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume3.26 million shs
Average Volume1.12 million shs
Market Capitalization$697.14 million
P/E Ratio11.47
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ATRS News and Ratings via Email

Sign-up to receive the latest news and ratings for Antares Pharma and its competitors with MarketBeat's FREE daily newsletter.

Antares Pharma logo

About Antares Pharma

Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therapeutic areas. It develops, manufactures, and commercialize novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and for glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto injectors; and drug/device product for urologic oncology and endocrinology. The company have strategic alliances and partnership arrangements pharmaceutical companies, including Pfizer, Idorsia, Teva, and AMAG. Antares Pharma, Inc. was founded in 1978 and is headquartered in Ewing, New Jersey.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.05 out of 5 stars

Medical Sector

64th out of 2,100 stocks

Surgical & Medical Instruments Industry

6th out of 174 stocks

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 3.1 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Antares Pharma (NASDAQ:ATRS) Frequently Asked Questions

Is Antares Pharma a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Antares Pharma in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Antares Pharma stock.
View analyst ratings for Antares Pharma
or view top-rated stocks.

What stocks does MarketBeat like better than Antares Pharma?

Wall Street analysts have given Antares Pharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Antares Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Antares Pharma's next earnings date?

Antares Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Antares Pharma

How were Antares Pharma's earnings last quarter?

Antares Pharma, Inc. (NASDAQ:ATRS) issued its quarterly earnings data on Wednesday, May, 5th. The specialty pharmaceutical company reported $0.02 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.01. The specialty pharmaceutical company had revenue of $42.08 million for the quarter, compared to analysts' expectations of $40.87 million. Antares Pharma had a trailing twelve-month return on equity of 17.47% and a net margin of 39.31%.
View Antares Pharma's earnings history

How has Antares Pharma's stock price been impacted by COVID-19 (Coronavirus)?

Antares Pharma's stock was trading at $3.00 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ATRS shares have increased by 37.7% and is now trading at $4.13.
View which stocks have been most impacted by COVID-19

What guidance has Antares Pharma issued on next quarter's earnings?

Antares Pharma issued an update on its FY 2021 earnings guidance on Thursday, May, 27th. The company provided EPS guidance of - for the period. The company issued revenue guidance of $175 million-$200 million, compared to the consensus revenue estimate of $187.23 million.

What price target have analysts set for ATRS?

4 equities research analysts have issued 12-month price objectives for Antares Pharma's shares. Their forecasts range from $5.00 to $7.00. On average, they anticipate Antares Pharma's stock price to reach $5.75 in the next year. This suggests a possible upside of 39.2% from the stock's current price.
View analysts' price targets for Antares Pharma
or view top-rated stocks among Wall Street analysts.

Who are Antares Pharma's key executives?

Antares Pharma's management team includes the following people:
  • Mr. Robert F. Apple, CEO, Pres & Director (Age 55, Pay $1M)
  • Mr. Fred M. Powell, Exec. VP & CFO (Age 60, Pay $636.39k)
  • Mr. Peter J. Graham, Exec. VP of HR, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 54, Pay $634.48k)
  • Mr. Patrick Madsen, Sr. VP of Operations
  • Mr. Keith Muckenhirn, Principal Accounting Officer, VP of Fin. & Corp. Controller (Age 58)
  • Ms. Tram Bui, VP of Corp. Communications & Investor Relations
  • Mr. Edward Tykot, Sr. VP of Corp. Bus. Devel.
  • Dr. Peter Sadowski, Sr. VP of Technology Portfolio & Intellectual Property (Age 73)
  • Dr. Jonathan S. Jaffe, Interim EVP, Pharmaceutical R&D and Chief Medical Officer
  • Mr. Greg Defilippis, Sr. VP of Device Bus. & Alliances

What is Paul K. Wotton's approval rating as Antares Pharma's CEO?

5 employees have rated Antares Pharma CEO Paul K. Wotton on Paul K. Wotton has an approval rating of 18% among Antares Pharma's employees. This puts Paul K. Wotton in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Antares Pharma's key competitors?

What other stocks do shareholders of Antares Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Antares Pharma investors own include Ballard Power Systems (BLDP), Advanced Micro Devices (AMD), Novavax (NVAX), (CGC), NVIDIA (NVDA), Conatus Pharmaceuticals (CNAT), Micron Technology (MU), Prospect Capital (PSEC), Gilead Sciences (GILD) and Sorrento Therapeutics (SRNE).

What is Antares Pharma's stock symbol?

Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS."

Who are Antares Pharma's major shareholders?

Antares Pharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.15%), Rubric Capital Management LP (5.17%), Centric Wealth Management (1.98%), Geode Capital Management LLC (1.57%), Nuveen Asset Management LLC (1.41%) and Northern Trust Corp (1.05%). Company insiders that own Antares Pharma stock include Fred M Powell, Leonard S Jacob, Marvin Samson, Peter J Graham, Robert F Apple and Thomas J Garrity.
View institutional ownership trends for Antares Pharma

Which institutional investors are selling Antares Pharma stock?

ATRS stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., AQR Capital Management LLC, Centric Wealth Management, Northern Trust Corp, Bank of Montreal Can, UBS Group AG, Schroder Investment Management Group, and Credit Suisse AG. Company insiders that have sold Antares Pharma company stock in the last year include Leonard S Jacob, Peter J Graham, Robert F Apple, and Thomas J Garrity.
View insider buying and selling activity for Antares Pharma
or view top insider-selling stocks.

Which institutional investors are buying Antares Pharma stock?

ATRS stock was bought by a variety of institutional investors in the last quarter, including Rubric Capital Management LP, Nuveen Asset Management LLC, Amundi Asset Management US Inc., Morgan Stanley, Putnam Investments LLC, Venator Capital Management Ltd., State Board of Administration of Florida Retirement System, and Dimensional Fund Advisors LP.
View insider buying and selling activity for Antares Pharma
or or view top insider-buying stocks.

How do I buy shares of Antares Pharma?

Shares of ATRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Antares Pharma's stock price today?

One share of ATRS stock can currently be purchased for approximately $4.13.

How much money does Antares Pharma make?

Antares Pharma has a market capitalization of $697.14 million and generates $149.60 million in revenue each year. The specialty pharmaceutical company earns $56.20 million in net income (profit) each year or $0.06 on an earnings per share basis.

How many employees does Antares Pharma have?

Antares Pharma employs 185 workers across the globe.

What is Antares Pharma's official website?

The official website for Antares Pharma is

Where are Antares Pharma's headquarters?

Antares Pharma is headquartered at 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628.

How can I contact Antares Pharma?

Antares Pharma's mailing address is 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628. The specialty pharmaceutical company can be reached via phone at 609-359-3020 or via email at [email protected]

This page was last updated on 6/19/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.